NZ336130A - Method for the crystallisation of a tetrahydropyridin derivative and resulting crystalline forms - Google Patents
Method for the crystallisation of a tetrahydropyridin derivative and resulting crystalline formsInfo
- Publication number
- NZ336130A NZ336130A NZ336130A NZ33613097A NZ336130A NZ 336130 A NZ336130 A NZ 336130A NZ 336130 A NZ336130 A NZ 336130A NZ 33613097 A NZ33613097 A NZ 33613097A NZ 336130 A NZ336130 A NZ 336130A
- Authority
- NZ
- New Zealand
- Prior art keywords
- crystalline forms
- crystallisation
- resulting crystalline
- carbon atoms
- tetrahydropyridin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Nutrition Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Toxicology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
A method of crystallizing a 1-[2-(2-naphthyl)ethyl]-4-(3-trifluoromethyl-phenyl)-1,2,3,6-tetrahydropyridine hydrochloride (SR 57746 A), the various crystalline forms obtained and pharmaceutical compositions containing them are described. The crystallization method comprises: (a) dissolving said compound by heating in a solvent selected from alkanols having 1 to 3 carbon atoms, ketones having 3 to 6 carbon atoms, dimethyl sulfoxide and ethyl acetate, said solvent optionally containing from 5 to 30% of water or aqueous hydrochloric acid, (b) cooling the resulting solution to -10/+10°C at a rate of 3 to 100°C/hour, with stirring at 0 to 600 rpm and (c) isolating and optionally micronizing the resulting product.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9615904A FR2757543B1 (en) | 1996-12-23 | 1996-12-23 | PROCESS FOR THE CRYSTALLIZATION OF A TETRAHYDROPYRIDINE DERIVATIVE AND CRYSTALLINE FORMS THUS OBTAINED |
| PCT/FR1997/002393 WO1998028271A1 (en) | 1996-12-23 | 1997-12-23 | Method for the crystallisation of a tetrahydopyridin derivative and resulting crystalline forms |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ336130A true NZ336130A (en) | 2001-01-26 |
Family
ID=9499043
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ336130A NZ336130A (en) | 1996-12-23 | 1997-12-23 | Method for the crystallisation of a tetrahydropyridin derivative and resulting crystalline forms |
Country Status (39)
| Country | Link |
|---|---|
| EP (1) | EP0950050B1 (en) |
| JP (2) | JP4499188B2 (en) |
| KR (1) | KR100586670B1 (en) |
| CN (1) | CN1129580C (en) |
| AR (1) | AR009672A1 (en) |
| AT (1) | ATE307802T1 (en) |
| AU (1) | AU736697B2 (en) |
| BR (1) | BR9714081A (en) |
| CA (1) | CA2275596C (en) |
| CO (1) | CO5070688A1 (en) |
| CZ (1) | CZ296689B6 (en) |
| DE (1) | DE69734460T2 (en) |
| DK (1) | DK0950050T3 (en) |
| DZ (1) | DZ2383A1 (en) |
| EE (1) | EE04188B1 (en) |
| EG (1) | EG21567A (en) |
| ES (1) | ES2251038T3 (en) |
| FR (1) | FR2757543B1 (en) |
| HK (1) | HK1024002A1 (en) |
| HR (1) | HRP970699B1 (en) |
| HU (1) | HU227425B1 (en) |
| IL (1) | IL129938A (en) |
| IN (1) | IN186976B (en) |
| IS (1) | IS2357B (en) |
| MY (1) | MY118015A (en) |
| NO (1) | NO312364B1 (en) |
| NZ (1) | NZ336130A (en) |
| PL (1) | PL190494B1 (en) |
| RS (1) | RS49882B (en) |
| RU (1) | RU2192416C2 (en) |
| SA (1) | SA98180971B1 (en) |
| SI (1) | SI0950050T1 (en) |
| SK (1) | SK285088B6 (en) |
| TR (1) | TR199901363T2 (en) |
| TW (1) | TW518322B (en) |
| UA (1) | UA60324C2 (en) |
| UY (1) | UY24825A1 (en) |
| WO (1) | WO1998028271A1 (en) |
| ZA (1) | ZA9711576B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2757543B1 (en) * | 1996-12-23 | 1999-04-02 | Sanofi Sa | PROCESS FOR THE CRYSTALLIZATION OF A TETRAHYDROPYRIDINE DERIVATIVE AND CRYSTALLINE FORMS THUS OBTAINED |
| FR2782082B3 (en) * | 1998-08-05 | 2000-09-22 | Sanofi Sa | CRYSTALLINE FORMS OF (R) - (+) - N - [[3- [1-BENZOYL-3- (3,4- DICHLOROPHENYL) PIPERIDIN-3-YL] PROP-1-YL] -4-PHENYLPIPERIDIN-4 - YL] -N-METHYLACETAMIDE (OSANETANT) AND PROCESS FOR THE PREPARATION OF SAID COMPOUND |
| JP5632906B2 (en) | 2010-03-12 | 2014-11-26 | 株式会社日本触媒 | Method for producing water absorbent resin |
| JP5870183B2 (en) * | 2011-04-15 | 2016-02-24 | エムキュア ファーマシューティカルズ リミテッド | Method for the synthesis of rilpivirine intermediate |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2531707A1 (en) * | 1982-08-16 | 1984-02-17 | Midy Spa | SUBSTITUTED TRIFLUOROMETHYLPHENYLTETRAHYDROPYRIDINES WITH ANOREXIGENIC ACTIVITY, A PREPARATION PROCESS AND PHARMACEUTICAL COMPOSITIONS |
| FR2757543B1 (en) * | 1996-12-23 | 1999-04-02 | Sanofi Sa | PROCESS FOR THE CRYSTALLIZATION OF A TETRAHYDROPYRIDINE DERIVATIVE AND CRYSTALLINE FORMS THUS OBTAINED |
-
1996
- 1996-12-23 FR FR9615904A patent/FR2757543B1/en not_active Expired - Fee Related
-
1997
- 1997-12-19 AR ARP970106029A patent/AR009672A1/en not_active Application Discontinuation
- 1997-12-22 MY MYPI97006233A patent/MY118015A/en unknown
- 1997-12-22 DZ DZ970233A patent/DZ2383A1/en active
- 1997-12-22 HR HR970699A patent/HRP970699B1/en not_active IP Right Cessation
- 1997-12-23 UA UA99063521A patent/UA60324C2/en unknown
- 1997-12-23 ES ES97952986T patent/ES2251038T3/en not_active Expired - Lifetime
- 1997-12-23 PL PL97334256A patent/PL190494B1/en not_active IP Right Cessation
- 1997-12-23 CA CA002275596A patent/CA2275596C/en not_active Expired - Fee Related
- 1997-12-23 ZA ZA9711576A patent/ZA9711576B/en unknown
- 1997-12-23 NZ NZ336130A patent/NZ336130A/en not_active IP Right Cessation
- 1997-12-23 RS YUP-289/99A patent/RS49882B/en unknown
- 1997-12-23 IL IL12993897A patent/IL129938A/en not_active IP Right Cessation
- 1997-12-23 AT AT97952986T patent/ATE307802T1/en active
- 1997-12-23 HU HU0001387A patent/HU227425B1/en not_active IP Right Cessation
- 1997-12-23 EP EP97952986A patent/EP0950050B1/en not_active Expired - Lifetime
- 1997-12-23 EE EEP199900264A patent/EE04188B1/en not_active IP Right Cessation
- 1997-12-23 DE DE69734460T patent/DE69734460T2/en not_active Expired - Lifetime
- 1997-12-23 TR TR1999/01363T patent/TR199901363T2/en unknown
- 1997-12-23 KR KR1019997005373A patent/KR100586670B1/en not_active IP Right Cessation
- 1997-12-23 AU AU56684/98A patent/AU736697B2/en not_active Ceased
- 1997-12-23 CZ CZ0229299A patent/CZ296689B6/en not_active IP Right Cessation
- 1997-12-23 WO PCT/FR1997/002393 patent/WO1998028271A1/en active IP Right Grant
- 1997-12-23 BR BR9714081-3A patent/BR9714081A/en not_active Application Discontinuation
- 1997-12-23 CO CO97074792A patent/CO5070688A1/en unknown
- 1997-12-23 SI SI9730720T patent/SI0950050T1/en unknown
- 1997-12-23 CN CN97180863A patent/CN1129580C/en not_active Expired - Fee Related
- 1997-12-23 JP JP52848198A patent/JP4499188B2/en not_active Expired - Fee Related
- 1997-12-23 UY UY24825A patent/UY24825A1/en not_active IP Right Cessation
- 1997-12-23 DK DK97952986T patent/DK0950050T3/en active
- 1997-12-23 EG EG138397A patent/EG21567A/en active
- 1997-12-23 IN IN3761DE1997 patent/IN186976B/en unknown
- 1997-12-23 RU RU99116597/04A patent/RU2192416C2/en not_active IP Right Cessation
- 1997-12-23 SK SK828-99A patent/SK285088B6/en not_active IP Right Cessation
-
1998
- 1998-01-21 TW TW086119629A patent/TW518322B/en not_active IP Right Cessation
- 1998-03-11 SA SA98180971A patent/SA98180971B1/en unknown
-
1999
- 1999-06-10 IS IS5076A patent/IS2357B/en unknown
- 1999-06-22 NO NO19993076A patent/NO312364B1/en not_active IP Right Cessation
-
2000
- 2000-06-01 HK HK00103287A patent/HK1024002A1/en not_active IP Right Cessation
-
2009
- 2009-05-07 JP JP2009112971A patent/JP2009197022A/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20022558L (en) | 4-Carboxyamino-2-ethyl-1,2,3,4-tetrahydroquinoline crystal as CETP inhibitor | |
| CA2429228A1 (en) | Improved sucralose composition and process for the crystallization thereof | |
| JPS6479151A (en) | Cyclic amine derivative | |
| NZ336130A (en) | Method for the crystallisation of a tetrahydropyridin derivative and resulting crystalline forms | |
| AU2001265377B2 (en) | Crystal modification of fexofenadine | |
| AU701221B2 (en) | Racemisation process for use in the manufacture of levobupivacaine and related piperidinecarboxanilide anaesthetic agents | |
| JPS6471816A (en) | Pharmacologically useful polymetamorphosis of buspirone | |
| CA2240201C (en) | Process for the preparation of felodipine | |
| WO2001002075A8 (en) | Method for using laser light to control crystal form | |
| EP1858847A1 (en) | Stable form i donepezil hydrochloride and process for its preparation and use in pharmaceutical compositions | |
| WO2000018722A3 (en) | New derivatives of 6-(4-phenylbutoxy)hexylamine and process for producing salmeterol | |
| JP2009535327A (en) | Ropivacaine hydrochloride anhydride and its preparation | |
| AP9801417A0 (en) | Piperidine acetic acid derivatives and their use in the treatment of thrombotic disorders. | |
| US3931184A (en) | Purification method for prolyl-leucylglycinamide | |
| NZ527138A (en) | 3-(3-amidinophenyl)-5-[({[1-(1-(-iminoethyl)-4-piperidyl}amino)methyl]benzoic acid dihydrochloride and process for preparing the same | |
| AU2001279834A1 (en) | A method of crystallizing maltitol | |
| RU99116597A (en) | A method for the crystallization of a tetrahydrin pyridine derivative and the crystalline forms obtained | |
| WO2001018028A8 (en) | Novel c13-substituted estra-1,3,5(10)-triene-3-yl-sulfamates, a method for producing the same and pharmaceutical compositions containing these compounds for inhibiting oestrone sulfatase | |
| US6015906A (en) | Dimethylamine benzoate or p-anisate catalysed process for the preparation of 4-(nitrophenyl)-dihydropyridines | |
| NO951477D0 (en) | Process for Preparation of Physically Stable Crystalline Gamma Modification of Para-Amino-Benzenesulfanylamides | |
| ES2265781B1 (en) | PROCEDURE FOR OBTAINING AMLODIPINE BESYLATE. | |
| DK1237841T3 (en) | Process for purifying lactic acid esters | |
| RU94043812A (en) | Derivatives of 1,4-dihydropyridine, mixture of their isomers or separate isomers and their salts, 2-chloro-3-cyano-benzaldehyde and pharmaceutical composition | |
| AU2001268157A1 (en) | Extractive solution crystallization of chemical compounds | |
| JPS646269A (en) | Quinoline derivative |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) | ||
| EXPY | Patent expired |